Live Feeds
● LIVE Updated 1h ago · 8 sources tracked

Vera kidney drug Trutakna shows strong final results in Phase 3 trial

Vera Therapeutics announced that its drug Trutakna (atacicept-vymj) stabilized kidney function and prevented disease progression in adults with primary IgA nephropathy. Final efficacy analysis from the two-year ORIGIN 3 Phase 3 trial shows the drug reduced the risk of IgAN progression by 76%. These results position the treatment for full regulatory approval. The data confirms that Trutakna stabilized eGFR and reduced the rate of kidney function decline over the 104-week study period.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Trutakna stabilized eGFR and prevented kidney disease progression through two years in the ORIGIN 3 trial.
  • ✓ Final data from the ORIGIN 3 trial shows atacicept cut IgAN progression risk by 76%.
  • ✓ Trutakna reduced the rate of kidney function decline in adults with primary IgA nephropathy.
  • ✓ The ORIGIN 3 trial results are based on a final 104-week analysis.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Vera Therapeutics released final 104-week efficacy data from the ORIGIN 3 Phase 3 trial.

Live updates

  1. Vera Therapeutics Reports Positive Phase 3 Results for Trutakna

    Vera Therapeutics announced that its drug Trutakna (atacicept-vymj) stabilized kidney function and prevented disease progression in adults with primary IgA nephropathy. Final efficacy analysis from the two-year ORIGIN 3 Phase 3 trial shows the drug reduced the risk of IgAN progression by 76%. These results position the treatment for full regulatory approval. The data confirms that Trutakna stabilized eGFR and reduced the rate of kidney function decline over the 104-week study period.

    Why it matters

    IgA nephropathy is a kidney disease that can lead to progressive renal failure. Trutakna aims to slow this decline to prevent the need for dialysis or transplants. Vera Therapeutics currently faces deepening rivalry with Vertex in this therapeutic space.

    What is confirmed

    • Trutakna stabilized eGFR and prevented kidney disease progression through two years in the ORIGIN 3 trial.
    • Final data from the ORIGIN 3 trial shows atacicept cut IgAN progression risk by 76%.
    • Trutakna reduced the rate of kidney function decline in adults with primary IgA nephropathy.
    • The ORIGIN 3 trial results are based on a final 104-week analysis.

    Still unconfirmed

    • Vera Therapeutics is experiencing a deepening rivalry with Vertex.

    What to watch next

    • Submission of Trutakna for full regulatory approval
    • Official FDA or EMA decision on the drug's market entry
    Sources used for this update (8)
    1. STAT — Vera kidney drug Trutakna shows strong final results in Phase 3 trial
    2. FirstWord Pharma — Positive data positions Vera's IgA nephropathy drug Trutakna for full approval
    3. Investor's Business Daily — Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?
    4. Yahoo Finance — Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
    5. HCPLive — Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data
    6. pulse2.com — Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results
    7. www.statnews.com — U.S. reaches highest number of measles deaths in decades
    8. www.empr.com — ORIGIN 3: Atacicept Reduces Kidney Function Decline in IgAN
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community